Burt Zweigenhaft

An innovator and accomplished chief executive in specialty biotech pharmaceuticals and oncology cancer care ecosystems for more than 26 years, Burt Zweigenhaft remains a trusted, independent, and respected key industry thought leader.

Mr. Zweigenhaft is Founder and current Executive Director of the Association for Value Based-Cancer Care, a 501(c)(6) educational organization to foster collaboration and the exchange of knowledge between all stakeholders in the cancer care. AVBCC beyond the Annual also orchestrates Regional Symposiums, Global Cancer Research and Innovation Symposium (GCRIS), Cell and Gene Therapy Commercialization Symposium (CGTCS) and the 40 Under 40 in Cancer Innovation Award events at ASCO.

Mr. Zweigenhaft also serves as the Managing Partner of The Mavericks Group; a Life and Health Services advisory practice focused on commercializing innovative biopharmaceuticals and elite technologies into healthcare ecosystems. Mr. Zweigenhaft is primarily focused on bringing about innovative Outcome Based Contracting Agreements between pharma, payers and physicians to the market.

Mr. Zweigenhaft was Founder, CEO, Vice Chairman of Onco360, the largest independent specialty oncology pharmaceuticals pharmacy provider with service revenues exceeding $9 billion.

Previously, Mr. Zweigenhaft was the Co-Founder and Past President of the National Association of Specialty Pharmacy (NASP), and Executive Director Enterprise Trade and Strategy for Cancer Treatment Centers of America (CTCA) now a part of City of Hope.

Mr. Zweigenhaft holds a DLitt, PhD from Alfred State College, along with a Bachelor of Science in Management and Economics from the University of Buffalo School of Management.

Philanthropically, Mr. Zweigenhaft serves on the National Board of Swim Across America a Cancer a Non-Profit 501(c)(3) with a primary mission to fund early on cancer research. SAA has funded over $188m to date supporting 48 cancer research laboratories today with some that have developed Opdivo, Keytruda and the unprecedented colorectal trail drug Jemperli. In 2015, Mr. Zweigenhaft was honored to be the recipient of the CancerCare’s “Help and Hope Award.”